Business Development 2002 – 2011

Total revenues by division

7,521

7,364

6,017

5,887

6,310

7,081

7,590

7,747

9,291

10,276

11

Pharmaceuticals

3,265

3,458

3,601

3,905

4,163

4,900

5,456

5,812

6,226

6,416

3.1

Merck Serono

1,850

1,546

1,619

1,817

1,938

4,480

5,014

5,345

5,754

5,920

2.9

Generics¹

1,096

1,585

1,625

1,712

1,825

–

–

–

–

–

–

Consumer Health Care

319

327

357

376

400

420

442

467

472

496

5.1

Chemicals

1,791

1,707

1,696

1,906

2,113

2,152

2,127

1,935

3,065

3,860

26

Merck Millipore

–

–

–

–

–

–

–

–

1,613⁴

2,393

48

Performance Materials

–

–

–

–

–

–

–

–

1,452⁴

1,467

1.0

Liquid Crystals²

383

443

589

741

895

916

878

733

–

–

–

Performance & Life Science Chemicals²

1,216

1,083

1,107

1,165

1,218

1,236

1,249

1,202

–

–

–

Electronic Chemicals¹

192

181

–

–

–

–

–

–

–

–

–

Laboratory Distribution¹

2,711

2,427

582

–

–

–

–

–

–

–

–

Intragroup sales, Laboratory

–246

–228

–62

–

–

–

–

–

–

–

–

Corporate and Other

–

–

200

76

34

29

7

–

–

–

–

Operating result by business sector

616

736

776

883

1,105

976

1,131

649

1,113

985

–12

Pharmaceuticals

272

389

391

454

524

417

655

403

579

350

–40

Chemicals

260

316

420

492

641

631

558

324

624

751

20

Laboratory Distribution¹

84

79

21

–

–

–

–

–

–

–

–

Corporate and Other

–

–48

–56

–63

–60

–72

–81

–78

–90

–116

30

Earnings before income and taxes (EBIT)

559

538

1,044

956

1,325

200

731

621

1,113

1,137

2.2

EBIT before depreciation and amortization (EBITDA)

985

1,008

1,419

1,245

1,628

1,858

1,947

1,625

2,457

2,736

11

Profit before tax

412

423

961

893

1,273

–111

575

486

861

851

–1.2

Profit after tax

215

218

672

673

1,001

3,520³

379

377

642

629

–2.0

Free cash flow

441

442

1,889

657

–1,073

–1,473³

438

812

–3,522

1,436

–

Capital expenditure on property, plant and equipment

377

281

234

268

253

283³

395

467

396

372

–6.1

Research and development

608

605

599

713

752

1,028

1,234

1,345

1,397

1,517

8.6

Total assets

7,511

6,982

5,754

7,281

8,102

14,922

15,645

16,713

22,388

22,120

–1.2

Net equity

2,054

2,363

2,800

3,329

3,807

8,688

9,563

9,514

10,372

10,493

1.2

Employees (number as of December 31)

34,504

34,206

28,877

29,133

29,999

30,968

32,800

33,062

40,562

40,676

0.3

Return on sales in % (ROS: Operating result / total revenues)

8.2

10.0

12.9

15.0

17.5

13.8

14.9

8.4

12.0

9.6

Earnings per share in €

1.18

1.15

3.47

3.40

5.07

16.21³

1.69

1.68

2.91

2.84

–2.4

Dividend per share in €

1.00

0.80

0.80

0.85

0.90

1.20

1.50

1.00

1.25

1.50

20

One-time bonus per share in €

–

–

0.20

–

0.15

2.00

–

–

–

–

–